Association between fibrosis markers and kidney function following peptide receptor radionuclide therapy in patients with neuroendocrine tumours

Tobias Stemann Lau, Lars Bossen, Daniel Guldager Kring Rasmussen, Morten Karsdal, Federica Genovese, Anne Kirstine Arveschoug, Henning Gronbaek, Gitte Dam

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


Peptide receptor radionuclide therapy (PRRT) is a treatment for neuroendocrine tumours (NET). Renal impairment is a known side effect due to kidney fibrosis. We investigated the association between novel specific fibrosis markers and kidney function following PRRT. We included 38 patients who had all finished PRRT. In serum and urine, we analysed levels of three different fibrosis markers, PRO-C6 (type VI collagen formation), PRO-C3 (type III collagen formation) and C3M (type III collagen degradation). We determined kidney function by the 51Cr-EDTA plasma clearance. We used Wilcoxon rank sum test and Spearman's rank correlation to evaluate the association between the fibrosis markers and kidney function. We included 38 NET patients, 25 small-intestinal NET, 6 pancreatic NET, 2 pulmonary NET and 5 other types of NET. Median age was 69 years (IQR: 61-73). Median time from last PRRT to inclusion was 8 months (IQR: 3-20). We found significantly increased levels of serum PRO-C6 (p = .007) and urinary PRO-C6 (p = .033) and significantly decreased levels of urinary C3M (p = .035) in patients with impaired kidney function. Further, we observed a negative association between serum PRO-C6 and kidney function (rho = -0.33, p = .04) and a positive association between urinary C3M and kidney function (rho = 0.37, p = .02). We showed an association between the three fibrosis markers, serum PRO-C6, urinary PRO-C6 and urinary C3M and kidney function. These markers may help to improve the understanding of potential pathological tissue turnover and potentially improve monitoring of kidney function after PRRT in NET patients.

Original languageEnglish
Book seriesScandinavian Journal of Clinical and Laboratory Investigation
Pages (from-to)446-453
Number of pages8
Publication statusPublished - Oct 2022


  • Aged
  • Biomarkers
  • Collagen Type III
  • Collagen Type VI
  • Complement C3
  • Edetic Acid
  • Fibrosis
  • Humans
  • Kidney/metabolism
  • Neuroendocrine Tumors/metabolism
  • Radioisotopes
  • Receptors, Peptide/metabolism


Dive into the research topics of 'Association between fibrosis markers and kidney function following peptide receptor radionuclide therapy in patients with neuroendocrine tumours'. Together they form a unique fingerprint.

Cite this